Product Description
Cangrelor (AR-C69931MX) is an intravenous, direct-acting and reversible P2Y(12) receptor antagonist. Cangrelor has a rapid onset and offset of action and achieves significantly greater degrees of platelet inhibition compared with clopidogrel. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19814662/)
Mechanisms of Action: P2Y12 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Denmark | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Luxembourg | Netherlands | Norway | Poland | Portugal | Romania | Slovakia | Slovenia | Spain | Sweden | Switzerland | Ukraine | United Kingdom | United States
Approved Indications: Coronary Thrombosis | Myocardial Infarction | Thrombosis
Known Adverse Events: Injuries/wounds Unspecified
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Acute Coronary Syndrome|Hypothermia|Angina, Stable|ST Elevation Myocardial Infarction|Cardiac Arrest|Angina, Unstable|Myocardial Infarction|Microvascular Angina|Coronary Artery Disease|Ischemic Stroke|Shock, Cardiogenic
Phase 3: Atherosclerosis|Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Coronary Thrombosis|Stroke|Angina, Unstable|Angina, Stable|Coronary Disease
Phase 2: Acute Coronary Syndrome|Myocardial Ischemia|Coronary Artery Disease|Injuries/wounds Unspecified|Reperfusion Injury|Cardiac Arrest|Myocardial Infarction|Shock, Cardiogenic
Phase 1: Healthy Volunteers|Pulmonary Heart Disease|Thrombosis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2024-512829-81-00 | P2 |
Unknown Status |
Cardiac Arrest|Shock, Cardiogenic |
2026-11-15 |
|
| MMI_2020_35 | P4 |
Unknown Status |
Ischemic Stroke |
2026-03-01 |
|
| ARMYDA TICA-MI | P4 |
Unknown Status |
Myocardial Infarction |
2025-12-31 |
|
| MIRACOR | P4 |
Recruiting |
Coronary Artery Disease |
2025-10-01 |